FR2134292A1 - Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine - Google Patents
Interferon compsns - contg halo desoxyuridines rifamycine or rifampycineInfo
- Publication number
- FR2134292A1 FR2134292A1 FR7115591A FR7115591A FR2134292A1 FR 2134292 A1 FR2134292 A1 FR 2134292A1 FR 7115591 A FR7115591 A FR 7115591A FR 7115591 A FR7115591 A FR 7115591A FR 2134292 A1 FR2134292 A1 FR 2134292A1
- Authority
- FR
- France
- Prior art keywords
- interferon
- rifampycine
- rifamycine
- days
- desoxyuridines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The use of a combination of interferon with a halodesoxuridine, rifamycine or rifampycine or their derivs., gives a greater antiviral effect than interferon alone. In an example, a patient suffering from a herpes infection of the cornea was treated with iodo-desoxyuridine and, after 5 days, with interferon followed by more iodo-desoxyridine. After three days an ulcer on the cornea had reduced in size by 2/3, and after 10 days was completely closed. The last application of interferon was made after 12 days.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7115591A FR2134292A1 (en) | 1971-04-30 | 1971-04-30 | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7115591A FR2134292A1 (en) | 1971-04-30 | 1971-04-30 | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2134292A1 true FR2134292A1 (en) | 1972-12-08 |
FR2134292B1 FR2134292B1 (en) | 1976-05-14 |
Family
ID=9076232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR7115591A Granted FR2134292A1 (en) | 1971-04-30 | 1971-04-30 | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2134292A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001102A1 (en) * | 1979-10-19 | 1981-04-30 | A Romano | Medicine for the treatment of viral infections of the eye and other organs |
EP0080032A2 (en) * | 1981-11-20 | 1983-06-01 | Enzo Biochem, Inc. | Pharmaceutical preparation for treating herpetic lesions |
EP0109234A1 (en) * | 1982-11-04 | 1984-05-23 | Syntex (U.S.A.) Inc. | Compositions comprising interferon and their therapeutic use |
EP0199451A2 (en) * | 1985-03-16 | 1986-10-29 | The Wellcome Foundation Limited | Therapeutic nucleosides |
WO2000057187A2 (en) * | 1999-03-19 | 2000-09-28 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
-
1971
- 1971-04-30 FR FR7115591A patent/FR2134292A1/en active Granted
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001102A1 (en) * | 1979-10-19 | 1981-04-30 | A Romano | Medicine for the treatment of viral infections of the eye and other organs |
EP0080032A2 (en) * | 1981-11-20 | 1983-06-01 | Enzo Biochem, Inc. | Pharmaceutical preparation for treating herpetic lesions |
EP0080032A3 (en) * | 1981-11-20 | 1985-11-13 | Enzo Biochem, Inc. | Pharmaceutical preparation for treating herpetic lesions |
EP0109234A1 (en) * | 1982-11-04 | 1984-05-23 | Syntex (U.S.A.) Inc. | Compositions comprising interferon and their therapeutic use |
EP0199451A2 (en) * | 1985-03-16 | 1986-10-29 | The Wellcome Foundation Limited | Therapeutic nucleosides |
EP0199451B1 (en) * | 1985-03-16 | 1996-03-06 | The Wellcome Foundation Limited | Therapeutic nucleosides |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
US7094397B2 (en) | 1997-08-14 | 2006-08-22 | Vanderbilt Unversity | Methods and reagents for the treatment of multiple sclerosis |
WO2000057187A2 (en) * | 1999-03-19 | 2000-09-28 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
WO2000057187A3 (en) * | 1999-03-19 | 2001-04-19 | Univ Vanderbilt | Diagnosis and treatment of multiple sclerosis |
Also Published As
Publication number | Publication date |
---|---|
FR2134292B1 (en) | 1976-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE7502341L (en) | ||
FR2134292A1 (en) | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine | |
CA931666A (en) | Patient treatment table | |
CA975903A (en) | Sperm oil substitute and its use in leather treatment | |
IL35811A0 (en) | O,s-dialkyl-o'-cyanophenyl-phosphorothiolates,their preparation and their use for controlling microorganisms | |
IL40933A0 (en) | Phenylformamidines,their manufacture and their use in pest control | |
GB1230455A (en) | ||
Restifo | The comparative morphology of the penis in the Libellulid genera Celithemis, Leucorrhinia, and Libellula (Odonata) | |
BARKHATOVA et al. | Treating the secretions of a human with the aid of a naturally forming algal-bacterial colony(Biological procession of human secretions and water regeneration by Chlorella in bacterial colony) | |
CA969175A (en) | 6.alpha.,9.alpha.-DIFLUOROSTEROIDS OF THE PREGNANE SERIES AND PROCESSES FOR THEIR MANUFACTURE | |
CA641909A (en) | 12.alpha.-ALKYL-17.alpha.,21-DIHYDROXY-1,4-PREGNADIENE-3,11,20-TRIONE AND 9.alpha.-HALO DERIVATIVES THEREOF | |
CA646287A (en) | 3-oxo-.delta.1,4 and .delta.1,4,6-steroids using 2,3-cyano-1,4-benzoquinones | |
AU277472B2 (en) | Improvements in or relating tothe manufacture of nonfibrous, hydrophilic films | |
AU2477262A (en) | Improvements in or relating tothe manufacture of nonfibrous, hydrophilic films | |
AU260396B2 (en) | Improvements in the processing of high cis-1,4 butadiene-1,3 polymers | |
AU1413162A (en) | Improvements in the processing of high cis-1,4 butadiene-1,3 polymers | |
AU451403B2 (en) | 'substituted1-(3',5-dihydroxyphenyl)-2-cycoalkyl amino butanol derivatives effectice in the treatment of bronchospastic conditions" | |
AU273555B2 (en) | Improvements in and relating tothe treatment of leather | |
CA618314A (en) | 1,1,2-trifluoroethylfluorosulfonate and fumigation process | |
AU274771B2 (en) | Improvements in or relating to 3, 4-benzoaporphine and derivatives thereof | |
CA643967A (en) | 9.alpha.-CHLORO- AND 9.alpha.-BROMO-11-OXO-5.alpha.-STEROIDS AND THEIR PREPARATION | |
CA866782A (en) | 16.alpha.-METHYL-9,11-OXIDO-17.alpha.,21-DIHYDROXY-1,4-PREGNADIENE-3,20-DIONE AND METHOD OF PREPARING THE SAME | |
CA621153A (en) | 3,3-disubstituted-2-azetidinones and manufacture thereof | |
AU1298670A (en) | 'substituted1-(3',5-dihydroxyphenyl)-2-cycoalkyl amino butanol derivatives effectice in the treatment of bronchospastic conditions" | |
AU3382763A (en) | Improvements in and relating tothe treatment of leather |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |